Quick Answer
Q32 Bio Inc. reported Net Income Loss of $29.82 million for the year ending 2025.
- Q32 Bio Inc. showed an increase of +162.5% in Net Income Loss from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$5.55 million | Q2 2017: -$6.00 million | Q3 2017: -$6.53 million | Q1 2018: -$10.22 million | Q2 2018: -$12.43 million | Q3 2018: -$14.15 million | Q1 2019: -$23.85 million | Q2 2019: -$26.27 million | Q3 2019: -$29.63 million | Q1 2020: -$35.33 million | Q2 2020: -$35.34 million | Q3 2020: -$28.23 million | Q1 2021: -$1.07 million | Q2 2021: -$30.50 million | Q3 2021: -$30.61 million | Q1 2022: $92.11 million | Q2 2022: -$29.09 million | Q3 2022: -$33.73 million | Q1 2023: -$6.84 million | Q2 2023: -$5.81 million | Q3 2023: -$14.03 million | Q1 2024: $1.03 million | Q2 2024: -$16.98 million | Q3 2024: -$17.60 million | Q1 2025: -$11.03 million | Q2 2025: $500.0 thousand | Q2 2025: -$9.49 million | Q3 2025: -$7.39 million.
- Over the full 9 years of available data (2017 to 2025), Q32 Bio Inc.'s Net Income Loss has grown by 199.4%.
- Historical annual values: Fiscal year 2025: $29.82 million | Fiscal year 2024: -$47.73 million | Fiscal year 2023: -$53.74 million | Fiscal year 2022: -$5.01 million | Fiscal year 2021: -$95.76 million | Fiscal year 2020: -$128.69 million | Fiscal year 2019: -$103.92 million | Fiscal year 2018: -$55.58 million | Fiscal year 2017: -$29.99 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: